A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Drug: Anti-EGFR-Containing Regimen; Drug: Chemotherapy; Drug: Bevacizumab-containing regimen

Study type: Observational

Funder types: Industry

Identifiers

NCT02831842

MO30177

Details and patient eligibility

About

This non-interventional study will meta-analyze overall survival outcomes among the participants with metastatic colorectal cancer (mCRC) with available V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) status, who received firstline treatment with bevacizumab containing treatment regimen in routine clinical practice. The study leveraging secondary data from existing cohorts in the United Stats of America (USA), Germany, Australia, and Denmark.

Enrollment: 4,278 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with metstatic colorectal cancer (mCRC) diagnosed at any point prior to March 2014 (United States [US] - Vector Oncology Protocol Sponsored by US Roche Pharma Medical Affairs), diagnosed between September 2006 and March 2015 (Germany - Tumourregister Kolorektales Karzinom [TKK] Registry Study Supported by German Roche Pharma Affiliate), diagnosed between September 2009 and December 2014 (Australia - Treatment of Recurrent and Advanced Colorectal Cancer [TRACC] Registry Supported by Roche Pharma Australia), diagnosed between 2009 and 2013 (Denmark - Roche Diagnostic Sponsored Study and Aarhus University Hospital, Department of Clinical Epidemiology)
• Participants have been treated in first line with bevacizumab or Anti-EGFR treatment regimen or chemotherapy alone
• Participants have to have available data on overall survival (OS), KRAS testing status, and left/right tumor location status

Exclusion criteria

N/A

Trial design

4,278 participants in 1 patient group

mCRC Participants

Description:

Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.

Treatment:

Drug: Chemotherapy

Drug: Bevacizumab-containing regimen

Drug: Anti-EGFR-Containing Regimen